Drug · DIN 02525852
MELVIZO
SINGLE-USE VIALS
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since November 7, 2025; first marketed March 1, 2023.
- Drug Identification Number (DIN)
- 02525852
- Company (DIN owner)
- Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Intravitreal
- Therapeutic class (ATC)
- Ranibizumab S01LA04
- Class
- Human
- Record last updated
- August 10, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RANIBIZUMAB | 10 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 7, 2025: NOC 36592Supplement to a New Drug Submission (SNDS) · Product name change
- March 8, 2022: NOC 27735New Drug Submission (NDS)